PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
09-Jan-2024 CD Biosciences Launches Substrate-Chromogens for Immunohistochemistry CD Biosciences
09-Jan-2024 STEMart Launches New Force Degradation Services to Ensure Drug Stability and Safety STEMart
09-Jan-2024 CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research CD Bioparticles
09-Jan-2024 CD Bioparticles Unveils Versatile Plain Polystyrene Particles for Diverse Bioresearch Applications CD Bioparticles
09-Jan-2024 Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research Creative Diagnostics
09-Jan-2024 Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness Creative Diagnostics
09-Jan-2024 Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues Creative Diagnostics
08-Jan-2024 Cell and Gene Therapy Catapult announces successful renewal of its five-year funding from Innovate UK to further support the advanced therapies sector The Cell and Gene Therapy Catapult
05-Jan-2024 LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in comp ADC Therapeutics
05-Jan-2024 selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024 selectION, Inc.
04-Jan-2024 PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease PharmaKure
04-Jan-2024 Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development Anocca AB
04-Jan-2024 Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates Vicore Pharma Holding AB
03-Jan-2024 AMLo Biosciences publish pivotal data for diagnostic biomarker technology AMBLor® in identifying melanomas at low risk of metastasis AMLo Biosciences
03-Jan-2024 iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference iTeos Therapeutics, Inc.
03-Jan-2024 Calibre Scientific Acquires LineaLAB Calibre Scientific
02-Jan-2024 Metabolomics Market Growing at a CAGR of 14.9% Say, Roots Analysis rootsanalysis
25-Dec-2023 Revolutionizing Healthcare: A Comprehensive Analysis of the MedTech Sector in 2024 Markets and Markets
21-Dec-2023 New partnership aims to advance vaccine against MERS coronavirus Barinthus Biotherapeutics
21-Dec-2023 FOR THE FIRST TIME, UK PATIENTS WITH AN ADVANCED FORM OF PROSTATE CANCER CAN ACCESS LYNPARZA (OLAPARIB) PLUS ABIRATERONE AND PREDNISONE OR PREDNISOLONE COMBINATION THERAPY WITHOUT THE NEED FOR A BIOMARKER TEST Astrazeneca